Is the FDA Too Cautious? episode artwork

EPISODE · Jul 21, 2023 · 53 MIN

Is the FDA Too Cautious?

from Open to Debate · host Open to Debate

While the Food and Drug Administration (FDA) needs to approve safe and effective drugs as quickly as possible to patients who need them, it must also maintain the diligence and rigor necessary to prevent harm. Two health experts look at the pace of FDA approvals and argue about whether the agency is getting it right on keeping the public safe or stifling health innovations. Now we debate: Is the FDA Too Cautious?  Arguing Yes: Colin Hill, CEO & Co-Founder, Aitia    Arguing No: Peter Lurie, President and Executive Director of Center for Science in the Public Interest   Emmy award-winning journalist John Donvan moderates    Learn more about your ad choices. Visit podcastchoices.com/adchoices

Episode metadata supplied by the publisher feed · Published Jul 21, 2023

Embed this episode

NOW PLAYING

Is the FDA Too Cautious?

0:00 53:15

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Open to Debate?

This episode is 53 minutes long.

When was this Open to Debate episode published?

This episode was published on July 21, 2023.

Can I download this Open to Debate episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!